New Vaccine Adoption in Lower-middle-income Countries

Lower-middle-income countries (LMICs) are lagging behind both high-income and low-income countries in new vaccine adoption. This study involved the following objectives: (1) understand the decision-making processes of LMICs on new vaccine adoption, (2) identify the factors influencing LMIC decisions, (3) obtain the views of vaccine manufacturers about LMIC markets for new vaccines, and (4) make recommendations concerning how to speed up and improve decision making, including proposing mechanisms for implementation of the recommendations,

Objectives: Lower-middle-income countries (LMICs) are lagging behind both high-income and low-income countries in new vaccine adoption. Our study involved the following objectives: (1) understand the decision-making processes of LMICs on new vaccine adoption, (2) identify the factors influencing LMIC decisions, (3) obtain the views of vaccine manufacturers about LMIC markets for new vaccines, and (4) make recommendations concerning how to speed up and improve decision making, including proposing mechanisms for implementation of the recommendations,

Methods: Collect and analyse qualitative data from participants in decision making in 15 case study countries [12 LMICs and three upper-middle-income countries (UMICs) and multinational and developing country vaccine manufacturers.

Findings: Interviews of actors in decision making indicate that the aspects deemed most important for adoption are: World Health Organization (WHO) recommendations, the existence of local epidemiological data and a set of factors comprising affordability, cost-effectiveness and overall cost of the new vaccine for the program. National Immunization Technical Advisory Groups (NITAG) have a key role in advising decision-makers, although their resources and capacity vary. Country decision-makers and manufacturers both see advantages in pooled procurement mechanisms for vaccine purchasing. Recommendations for countries and the international community involve assisting with making epidemiological data and vaccine market information accessible to countries, building and reinforcing related analysis capacity, and assisting with purchasing mechanisms and practices such as pooled procurement.

If you require assistance in obtaining the full paper, please reach out to the Network Coordinators.

You May Also Like

Scoping Review of Current Costing Literature on Interventions to Reach Zero-Dose Children in Low- and Middle-Income Countries

A study in Vaccines analyzes the costs and effectiveness of interventions aimed at reaching zero-dose children—those who have not received any routine vaccinations—in low- and middle-income countries (LMICs). The research evaluates strategies such as mobile outreach, community engagement, and health system strengthening, highlighting their cost-effectiveness in improving immunisation coverage. The findings suggest that tailored, context-specific … Read More

Private sector engagement for immunisation programs: a pragmatic scoping review of 25 years of evidence on good practice in low-income and middle-income countries

A study in BMJ Global Health explores the role of private sector engagement in strengthening immunisation programs in low- and middle-income countries (LMICs). The research highlights that partnerships with private healthcare providers, pharmacies, and businesses can expand vaccine access, improve service delivery, and increase coverage. Key strategies include leveraging private sector infrastructure, integrating public-private data … Read More

Socioeconomic-related inequities in child immunisation: horizontal and vertical dimensions for policy insights

A study in Health Economics Review investigates the economic and equity impacts of expanding immunisation programs in low- and middle-income countries (LMICs), focusing on the cost-effectiveness of introducing new vaccines. The research highlights that while scaling up immunisation efforts requires significant investment, the long-term benefits—such as reduced disease burden, healthcare savings, and improved productivity—justify the … Read More